News

CEPI expands collaboration to develop COVID-19 multi-variant vaccine

OSLO, Norway, SHANGHAI and KUNMING, China; 8 February 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it will expand its collaboration with Shanghai Zerun Biotechnology Co., Ltd. (Zerun Bio) and its parent company Walvax Biotechnology Co., Ltd. (Walvax), a public company listed on the Shenzhen Stock Exchange (300142.SZ) to advance the development of...

08 Feb 2022

CEPI opens Call to develop heat-stable vaccine tech

The aim is to use these new tools to improve global access to vaccines through reducing complex-cold chain requirements and potential vaccine wastage.

08 Feb 2022

CEPI partners with BioNet to expand variant-proof vaccine programme

The award is part of CEPI’s $200m programme to advance the development of broadly protective coronavirus vaccines. OSLO, Norway, 25 January 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched in March 2021, to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants...

25 Jan 2022

Bill & Melinda Gates Foundation and Wellcome pledge $300 million to CEPI

New funding commitments will support CEPI’s goal to condense new vaccine development timelines to 100 days, a third of the time it took to develop a COVID-19 vaccine. Pledges contribute towards CEPI’s $3.5billion replenishment target, set for a Global Pandemic Preparedness Summit to be hosted by the UK Government in March 2022.

19 Jan 2022

CEPI expands partnership with SK bio for ‘variant-proof’ vaccine

CEPI will provide up to $50 million to support the development of a vaccine candidate based on SK’s nanoparticle vaccine platform that could protect against variants of both SARS-CoV, SARS-CoV-2, and other sarbecoviruses.

21 Dec 2021

Reflections on 2021 from CEPI CEO Dr Richard Hatchett

Dr Richard Hatchett offers his personal reflections on the events of the past year, and looks to the challenges ahead as the world responds to Omicron and prepares for the threat of future pandemics.

21 Dec 2021

CEPI partners with Affinivax to develop a novel COVID-19 vaccine to target variants

New partnership will advance the development of a novel vaccine that could provide broad protection against SARS-CoV-2 variants, and potentially other betacoronaviruses.

13 Dec 2021

1 2 3 4 5 6